Skip to Content
chevron-left chevron-right chevron-up chevron-right chevron-left arrow-back star phone quote checkbox-checked search wrench info shield play connection mobile coin-dollar spoon-knife ticket pushpin location gift fire feed bubbles home heart calendar price-tag credit-card clock envelop facebook instagram twitter youtube pinterest yelp google reddit linkedin envelope bbb pinterest homeadvisor angies

USOR #20186

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial (BO41932).

This trial is for patients with solid tumors that are advanced and unresectable or metastatic disease.

Cohort A: ROS1 fusion

  • NSCLC excluded

Cohort B: NTRK 1/2/3 fusion

  • Prior treatment with NTRK inhibitors Excluded

Cohort C ALK fusion-positive tumors

  • NSCLC and neuroblastoma excluded. Prior treatment with a ALK inhibitor excluded